Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Corcept TherapeuticsFRA:HTD -1.99%85 3-Year Book Growth Rate is 9.50% as of Jun. 2026, which is 25% below its 10-year median of 12.70. GuruFocus rates FRA:HTD with a GF Score™ of 85/100 and a GF Value™ of €60.80 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 1,131 Biotechnology companies, Corcept Therapeutics ranks better than 77.45% on this metric.
During the past 12 months, Corcept Therapeutics's average Book Value per Share Growth Rate was 8.30% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 9.50% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 10.20% per year.
During the past 10 years, the average Book Value per Share Growth Rate was 36.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Corcept Therapeutics was 142.10% per year. The lowest was -43.10% per year. And the median was 12.70% per year.
Corcept Therapeutics (FRA:HTD) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Corcept Therapeutics 3-Year Book Growth Rate Related Terms
FRA:HTD vs APGE, KRYS, NUVL: 3-Year Book Growth Rate Comparison
For the Biotechnology subindustry, Corcept Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corcept Therapeutics 3-Year Book Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Corcept Therapeutics's 3-Year Book Growth Rate falls into.
Corcept Therapeutics 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 9.50% mean?
Corcept Therapeutics (FRA:HTD) has a 3-Year Book Growth Rate of 9.50% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Corcept Therapeutics and its competitors. This is 25% below median its historical median of 12.70. According to the industry distribution chart, Corcept Therapeutics ranks #255 out of 1131 companies in the Biotechnology industry, placing it in the top 22.5%.
Is Corcept Therapeutics' 3-Year Book Growth Rate too high?
Corcept Therapeutics' current 3-Year Book Growth Rate of 9.50% is 25% below median its 10-year median of 12.70. Based on the distribution chart, Corcept Therapeutics ranks #255 out of 1131 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Corcept Therapeutics has a GF Score™ of 85/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' 3-Year Book Growth Rate compare to APGE and KRYS?
According to the Biotechnology industry distribution chart, Corcept Therapeutics ranks #255 out of 1131 companies for 3-Year Book Growth Rate. This places Corcept Therapeutics in the top 23% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Corcept Therapeutics and its competitors. Corcept Therapeutics's current 3-Year Book Growth Rate is 9.50%, which is 25% below median its own 10-year median of 12.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Corcept Therapeutics (FRA:HTD) is currently considered Significantly Overvalued. The stock's GF Value™ is €60.80, compared to a current price of €98.16 — trading 61.4% above its estimated fair value. The current 3-Year Book Growth Rate is 9.50%, which is 25% below median its 10-year median of 12.70. Corcept Therapeutics' overall GF Score™ is 85/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Corcept Therapeutics (FRA:HTD), the current 3-Year Book Growth Rate is 9.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corcept Therapeutics (FRA:HTD) Overvalued in 2026?
Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued.
The current stock price of €98.16 is trading 61.4% above its estimated GF Value™ of €60.80.
GuruFocus considers Corcept Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:HTD:
3-Year Book Growth Rate: 9.50% (25% below median its 10-year median of 12.70)
GF Value™: €60.80 vs. price of €98.16 (61.4% above fair value)
No single metric tells the full story. See the FRA:HTD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
85GF Score
Get the complete analysis for FRA:HTD
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:HTD has been successfully added to your 
